---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005262"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:11:00.783673+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Reports Q2 2025 Revenue of $20.5M, Net Loss of $2.3M, and Credit Amendment

## Summary
- Q2 2025 revenue of $20.5M vs $23.1M in Q2 2024; gross margin 56.4% vs 57.2%.
- Net loss improved to ($2.3M) from ($2.9M); adjusted EBITDA rose to $1.5M from $1.3M.
- Cash from operations was $2.8M, compared to ($0.8M) in Q2 2024.
- Credit agreement amended waiving defaults; new refinance deadline set for December 5, 2025.
- Q3 2025 revenue guidance $19M-$21M with gross margin 56%-58%.

## SEC filing metadata
- accession: 0001171843-25-005262
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184325005262/0001171843-25-005262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184325005262/f8k_080525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005262
- JSON: https://secwatch.observer/filing/0001171843-25-005262.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005262.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.